연구용

AZD1480 JAK 억제제

제품 번호S2162

AZD1480은 무세포 분석에서 0.26 nM의 IC50을 가진 새로운 ATP 경쟁적 JAK2 억제제이며, JAK3 및 Tyk2에 대해 선택성을 가지며 JAK1에 대해서는 더 적은 정도의 선택성을 가진다. 1단계.
AZD1480 JAK 억제제 Chemical Structure

화학 구조

분자량: 348.77

바로가기

품질 관리

배치: 순도: 99.16%
99.16

세포 배양, 처리 및 작업 농도

세포주 분석 유형 농도 배양 시간 제형 활성 설명 PMID
SW620 Function Assay 5 μM 48 h DMSO blocks JAK2/STAT3 signaling 25954974
LoVo  Function Assay 5 μM 48 h DMSO blocks JAK2/STAT3 signaling 25954974
HN5 Growth Inhibition Assay 72 h EC50=3.81 ± 1.99 μM 25810010
Cal33 Growth Inhibition Assay 72 h EC50=3.37 ± 0.75 μM 25810010
UM-22B Growth Inhibition Assay 72 h EC50=2.66 ± 0.24 μM 25810010
686LN Growth Inhibition Assay 72 h EC50=2.05 ± 1.33 μM 25810010
UM SCC-1 Growth Inhibition Assay 72 h EC50=1.67 ± 0.42 μM 25810010
UM-22A Growth Inhibition Assay 72 h EC50=1.32 ± 0.39 μM 25810010
OSC19 Growth Inhibition Assay 72 h EC50=1.26 ± 0.20 μM 25810010
PCI-52 Growth Inhibition Assay 72 h EC50=1.00 ± 0.09 μM 25810010
PCI-15B Growth Inhibition Assay 72 h EC50=0.99 ± 1.74 μM 25810010
UMSCC-1 Function Assay 0.0005-1.6 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner 25810010
Cal33 Function Assay 0.0005-3.8 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner 25810010
HH5 Function Assay 0.0005-3.8 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner 25810010
UM-22A Function Assay 0.0005-1.6 μM 24 h abrogates IL-6–induced up-regulation of pSTAT3Tyr705 in a dose-dependent manner 25810010
A1847 Function Assay 0.05-10 μM 24 h DMSO  reduces phosphorylated STAT3 levels 25646015
OVCAR-5 Function Assay 0.05-10 μM 24 h DMSO  reduces phosphorylated STAT3 levels 25646015
OVCAR-8 Function Assay 0.05-10 μM 24 h DMSO  reduces phosphorylated STAT3 levels 25646015
MOVCAR-5447 Function Assay 0.05-10 μM 24 h DMSO  reduces phosphorylated STAT3 levels 25646015
MOVCAR-5009 Function Assay 0.05-10 μM 24 h DMSO  reduces phosphorylated STAT3 levels 25646015
A1847 Cell Viability Assay 0.05-10 μM 72 h DMSO reduces cell viability at the concerntration of 5 μM 25646015
OVCAR-5 Cell Viability Assay 0.05-10 μM 72 h DMSO reduces cell viability at the concerntration of 5 μM 25646015
OVCAR-8  Cell Viability Assay 0.05-10 μM 72 h DMSO reduces cell viability at the concerntration of 5 μM 25646015
OVCAR-5  Apoptosis Assay 0.5/1/5 μM 48 h DMSO induces significant apoptosis at high concerntration 25646015
OVCAR-8  Apoptosis Assay 0.5/1/5 μM 48 h DMSO induces significant apoptosis at high concerntration 25646015
AKRSL Cell Viability Assay 72 h IC50>10 μM 25504635
PALJDL Cell Viability Assay 72 h IC50=2.4 μM 25504635
MO4 Function Assay 0.5/1/5 μM 6 h inhibits P-STAT3 expression  25149535
DU145  Function Assay 0-200 nM 1 h  suppresses IL-6-activated Stat3 and ERK1/2 signaling 24577942
DU145  Function Assay 800 nM 72 h suppresses IL-6-induced migratory 24577942
CWR22Rv1 Function Assay 800 nM 72 h suppresses IL-6-induced migratory 24577942
N592 Growth Inhibition Assay IC50=0.84 μM 24158701
H82 Growth Inhibition Assay IC50=1.37 μM 24158701
GLC4 Growth Inhibition Assay IC50=1.79 μM 24158701
H526 Growth Inhibition Assay IC50=3.08 μM 24158701
H1173 Growth Inhibition Assay IC50=2.39 μM 24158701
DMS114 Growth Inhibition Assay IC50=0.73 μM 24158701
NCI-N592 Function Assay 0.3/1/3 μM 24 h induces G2/M cell cycle arrest 24158701
GLC4 Function Assay 0.3/1/3 μM 24 h induces G2/M cell cycle arrest 24158701
NCI-H82 Function Assay 0.3/1/3 μM 24 h induces G2/M cell cycle arrest 24158701
NCI-N592 Apoptosis Assay 0.3/1/3 μM 48 h increases the level of cleaved-Caspase 3 24158701
GLC4 Apoptosis Assay 0.3/1/3 μM 48 h increases the level of cleaved-Caspase 3 24158701
NCI-H82 Apoptosis Assay 0.3/1/3 μM 48 h increases the level of cleaved-Caspase 3 24158701
CWR22Rv1  Apoptosis Assay IC50=0.482 μM 23942095
CWR22Pc Apoptosis Assay IC50=0.438 μM 23942095
PC-3 Apoptosis Assay IC50=1.755 μM 23942095
DU145 Apoptosis Assay IC50=3.517 μM 23942095
RC165N Apoptosis Assay IC50=2.083 μM 23942095
ARPE19 Growth Inhibition Assay DMSO IC50=24.38 μM 23531921
HEK293 Growth Inhibition Assay DMSO IC50=8.67 μM 23531921
KCNR Growth Inhibition Assay DMSO IC50=0.46 μM 23531921
SY5Y Growth Inhibition Assay DMSO IC50=0.36 μM 23531921
BE2 Growth Inhibition Assay DMSO IC50=0.71 μM 23531921
AS Growth Inhibition Assay DMSO IC50=1.53 μM 23531921
NGP Growth Inhibition Assay DMSO IC50=0.56 μM 23531921
IMR32 Growth Inhibition Assay DMSO IC50=0.66 μM 23531921
LAN5 Growth Inhibition Assay DMSO IC50=1.04 μM 23531921
RH18 Growth Inhibition Assay DMSO IC50=1.42 μM 23531921
RH30 Growth Inhibition Assay DMSO IC50=1.25 μM 23531921
RH17 Growth Inhibition Assay DMSO IC50=2.51 μM 23531921
RH28 Growth Inhibition Assay DMSO IC50=4.28 μM 23531921
RH36 Growth Inhibition Assay DMSO IC50=5.37 μM 23531921
RH41 Growth Inhibition Assay DMSO IC50=0.48 μM 23531921
RD Growth Inhibition Assay DMSO IC50=4.32 μM 23531921
TC32 Growth Inhibition Assay DMSO IC50=3.85 μM 23531921
TC71 Growth Inhibition Assay DMSO IC50=4.33 μM 23531921
KCNR Apoptosis Assay 0.5/1.0/2.5 μM 24 h DMSO induces an increase in caspase 3/7 activity 23531921
SY5Y Apoptosis Assay 0.5/1.0/2.5 μM 24 h DMSO induces an increase in caspase 3/7 activity 23531921
Rh18 Apoptosis Assay 0.5/1.0/2.5 μM 24 h DMSO induces an increase in caspase 3/7 activity 23531921
TC32 Apoptosis Assay 0.5/1.0/2.5 μM 24 h DMSO induces an increase in caspase 3/7 activity 23531921
KCNR Function Assay 0.5/1.0/2.5/5 μM 24 h DMSO inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
SY5Y Function Assay 0.5/1.0/2.5/5 μM 24 h DMSO inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
Rh18 Function Assay 0.5/1.0/2.5/5 μM 24 h DMSO inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
TC32 Function Assay 0.5/1.0/2.5/5 μM 24 h DMSO inhibits both endogenous constitutive and IL-6-induced STAT3 activation 23531921
TPC-1 Growth Inhibition Assay 1 µM 0-4 d DMSO inhibits cell growth after 2 d treatment 23056499
MZ-CRC1  Growth Inhibition Assay 1 µM 0-5 d DMSO inhibits cell growth after 1 d treatment 23056499
TT  Growth Inhibition Assay 1 µM 0-4 d DMSO inhibits cell growth after 1 d treatment 23056499
TPC-1 Function Assay 1 µM 72 h DMSO induces G1 blockage 23056499
MZ-CRC1  Function Assay 1 µM 72 h DMSO induces G1 blockage 23056499
TT  Function Assay 1 µM 72 h DMSO induces G1 blockage 23056499
MZ-CRC1  Apoptosis Assay 1 µM 48 h DMSO induces apoptosis 23056499
TT  Apoptosis Assay 1 µM 48 h DMSO induces apoptosis 23056499
HD-LM2 Growth Inhibition Assay 72 h DMSO IC50=7.844 μM 22829094
L-428 Growth Inhibition Assay 72 h DMSO IC50=7.947 μM 22829094
KM-H2 Growth Inhibition Assay 72 h DMSO IC50=1.308 μM 22829094
L-540 Growth Inhibition Assay 72 h DMSO IC50=8.216 μM 22829094
HD-LM2 Function Assay 0.1/0.5/1/5 μM 72 h DMSO inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
L-428 Function Assay 0.1/0.5/1/5 μM 72 h DMSO inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
KM-H2 Function Assay 0.1/0.5/1/5 μM 72 h DMSO inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
L-540 Function Assay 0.1/0.5/1/5 μM 72 h DMSO inhibits STAT3, STAT5 and STAT6 phosphorylation 22829094
HD-LM2 Apoptosis Assay 1/5 μM 72 h DMSO induces apoptosis 22829094
L-428 Apoptosis Assay 1/5 μM 72 h DMSO induces apoptosis 22829094
KM-H2 Apoptosis Assay 1/5 μM 72 h DMSO induces apoptosis 22829094
L-540 Apoptosis Assay 1/5 μM 72 h DMSO induces apoptosis 22829094
U251-MG Function Assay 1 µM 0-16 h inhibits constitutive STAT-3 and JAK2 activation 22027691
U87-MG Function Assay 1 µM 0-16 h inhibits constitutive STAT-3 and JAK2 activation 22027691
4C8 Function Assay 1 µM 0-16 h inhibits constitutive STAT-3 and JAK2 activation 22027691
U251-MG Growth Inhibition Assay 1/10 µM 24/48/72 h inhibits cell proliferation at a concentration of 10 µM 22027691
U87-MG Growth Inhibition Assay 1/10 µM 24/48/72 h inhibits cell proliferation at a concentration of 10 µM 22027691
4C8 Growth Inhibition Assay 1/10 µM 24/48/72 h inhibits cell proliferation at a concentration of 10 µM 22027691
U266 Apoptosis Assay 0.5-2 μM 48/72 h induces apoptosis dose dependently 21164517
Kms.11 Apoptosis Assay 0.5-2 μM 48/72 h induces apoptosis dose dependently 21164517
8226 Apoptosis Assay 0.5-2 μM 48/72 h induces apoptosis dose dependently 21164517
SET2 Growth inhibition assay 48 hrs Growth inhibition of human SET2 cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.016 μM. 21138246
SET2 Function assay 1 hr Inhibition of Stat3 phosphorylation in human SET2 cells after 1 hr by Western blotting, IC50 = 0.023 μM. 21138246
SET2 Function assay 1 hr Inhibition of Stat5 phosphorylation in human SET2 cells after 1 hr by Western blotting, IC50 = 0.025 μM. 21138246
HEL Function assay 1 hr Inhibition of Stat5 phosphorylation in human HEL cells after 1 hr by Western blotting, IC50 = 0.041 μM. 21138246
Ba/F3 Function assay Inhibition of Stat5 phosphorylation in mouse Ba/F3 cells expressing TEL-Jak2, IC50 = 0.046 μM. 21138246
UKE1 Growth inhibition assay 48 hrs Growth inhibition of human UKE1 cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.054 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-JAK2 kinase after 48 hrs by MTS assay, GI50 = 0.06 μM. 21138246
HEL Function assay 1 hr Inhibition of Stat3 phosphorylation in human HEL cells after 1 hr by Western blotting, IC50 = 0.08 μM. 21138246
HEL Growth inhibition assay 48 hrs Growth inhibition of human HEL cells expressing Jak2 V617F mutant after 48 hrs by MTS assay, GI50 = 0.39 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-JAK1 kinase after 48 hrs by MTS assay, GI50 = 0.7 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-Tyk2 kinase after 48 hrs by MTS assay, GI50 = 2 μM. 21138246
BA/F3 Growth inhibition assay 48 hrs Growth inhibition of mouse BA/F3 cells expressing Tel-JAK3 kinase after 48 hrs by MTS assay, GI50 = 2.1 μM. 21138246
UKE1 Function assay 1 hr Inhibition of Stat5 phosphorylation in human UKE1 cells after 1 hr by Western blotting 21138246
SW620 Cell cycle assay 3.3 uM 24 hrs Cell cycle arrest in human SW620 cells assessed as accumulation at G2/M phase at 3.3 uM after 24 hrs by flow cytometry 21138246
HEL Function assay 0.3 uM 5 mins Inhibition of Stat5 phosphorylation in human HEL cells at 0.3 uM after 5 mins by Western blotting 21138246
HEL Function assay 0.3 uM 30 to 60 mins Inhibition of Stat5 phosphorylation in human HEL cells at 0.3 uM after 30 to 60 mins by Western blotting 21138246
BA/F3 Antitumor assay 30 mg/kg 12 hrs Antitumor activity against mouse BA/F3 cells expressing Tel-JAK2 xenografted in NCr mouse assessed as reduction of phosphorylated Stat5 level in spleen at 30 mg/kg, po after 12 hrs by Western blotting 21138246
HEL Function assay 0.3 uM 5 mins Inhibition of Stat3 phosphorylation in human HEL cells at 0.3 uM after 5 mins by Western blotting 21138246
HEL Function assay 0.3 uM 30 to 60 mins Inhibition of Stat3 phosphorylation in human HEL cells at 0.3 uM after 30 to 60 mins by Western blotting 21138246
Hs578T Function assay 1 uM 24 hrs Inhibition of STAT3C-mediated transcription in human Hs578T cells at 1 uM after 24 hrs by luciferase reporter gene assay 24978112
NCI-H1975 Function assay 0.003 to 3 uM 2 hrs Inhibition of JAK1 in human NCI-H1975 cells assessed as reduction in STAT3 phosphorylation at 0.003 to 3 uM after 2 hrs by Western blot analysis 26614408
HEL 92.1.7 Function assay 2 hrs Inhibition of JAK2 in human HEL 92.1.7 cells assessed as reduction in STAT5 phosphorylation after 2 hrs by Western blot analysis 26614408
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성

분자량 348.77 화학식

C14H14ClFN8

보관 (수령일로부터)
CAS 번호 935666-88-9 SDF 다운로드 원액 보관

동의어 N/A Smiles CC1=CC(=NN1)NC2=NC(=NC=C2Cl)NC(C)C3=NC=C(C=N3)F

용해도

In vitro
배치:

DMSO : 70 mg/mL (200.7 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : Insoluble

Ethanol : Insoluble

몰농도 계산기

질량 농도 부피 분자량
희석 계산기 분자량 계산기

In vivo
배치:

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

mg/kg g μL

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘

Targets/IC50/Ki
JAK2
(Cell-free assay)
0.26 nM
시험관 내(In vitro)
5μM AZD1480은 Aurora 키나아제를 억제하여 G2/M기 정지 및 세포 사멸을 유도합니다. 이 화합물은 인간 다발성 골수종 세포에서 성장, 생존뿐만 아니라 FGFR3 및 STAT3 신호 전달 및 Cyclin D2를 포함한 하위 표적을 억제할 수 있는 강력한 JAK2 억제제입니다. 낮은 마이크로몰 농도에서 세포 증식을 차단하고 골수종 세포주의 세포 사멸을 유도합니다. 이 화학물질은 인간 및 쥐의 신경교종 세포에서 구성적 및 자극 유도 JAK1, JAK2 및 STAT-3 인산화를 효과적으로 차단하여 세포 증식 감소 및 세포 사멸 유도를 유도합니다. 이것은 강력하고 경쟁적인 JAK1/2 키나아제 소분자 억제제이며, STAT3 인산화 및 STAT3 의존적 방식으로 종양 성장을 억제할 수 있습니다. 이 억제제는 부분적으로 종양 미세 환경에 영향을 미쳐 종양 혈관 신생 및 전이를 억제합니다.
키나아제 분석
키나아제 분석
AZD1480의 억제 연구는 50 mM HEPES pH 7.3, 1 mM DTT, 0.01% Tween-20, 50 mM/ml BSA, 10 mM MgCl2 완충 조건에서 재조합 Jak1, Jak2 또는 Jak3를 사용하여 수행됩니다. Jak3 효소는 곤충 세포에서 N-말단 GST 융합으로 발현되고 글루타치온 친화성 및 크기 배제 크로마토그래피로 정제됩니다. 효소는 이 화합물 존재 하에 (8.3 μM에서 0.3 nM까지 반대수 희석 단계에서 10점 용량 반응, 삼중 반복) 1.5 μM 펩타이드 기질 (Jak1: FITC-C6-KKHTDDGYMPMSPGVA-NH2, Jak2 및 Jak3: FAM-SRCtide)을 사용하여 분석되었고 각각의 ATP Km (Jak1: 55 μM, Jak2: 15 μM, Jak3: 3 μM) 및 약 5 mM의 생리학적 ATP 농도에서 스크리닝되었습니다. 인산화된 펩타이드와 비인산화된 펩타이드는 Caliper LC3000 시스템으로 분리 및 정량화하여 억제율을 계산했습니다.
생체 내(In vivo)
AZD1480은 인간 고형암 및 다발성 골수종의 이종이식 모델에서 STAT3 인산화를 억제합니다. 생체 내에서 이 화합물은 피하 종양의 성장을 억제하고 STAT-3 활성을 억제하여 두개내 교모세포종(GBM) 종양을 가진 생쥐의 생존을 증가시킵니다. 이는 이 화학물질에 의한 JAK/STAT-3 경로의 약리학적 억제가 GBM 종양 환자 치료 연구에 고려되어야 함을 나타냅니다. 그것은 마우스 동계 실험 및 자발적 전이 모델 모두에서 골수성 세포의 폐 침윤 및 폐 전이 형성을 차단합니다. 또한, 이 약물은 인간 이종이식 종양 모델에서 혈관 신생 및 전이를 감소시킵니다. Jak2 억제제는 지속적인 Stat3 활성을 보유하는 인간 고형 종양 이종이식편의 성장을 억제합니다.
참조
  • [4] https://pubmed.ncbi.nlm.nih.gov/21920898/
  • [5] https://pubmed.ncbi.nlm.nih.gov/19962667/

적용 분야

방법 바이오마커 이미지 PMID
Western blot p-STAT3 / STAT3 / p-JAK2 / JAK2 p-STAT1 / STAT1 / p-STAT5 / STAT5 / p-STAT6 / STAT6 p-ERK / ERK / p-p38 / p38 / SOCS3 / p-SHP2 / SHP2
S2162-WB1
22027691
Immunofluorescence pSTAT5
S2162-IF1
30140255
Growth inhibition assay Cell proliferation Cell viability
S2162-viability1
22027691

임상시험 정보

(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)

NCT 번호 모집 조건 스폰서/협력자 시작일 단계
NCT01219543 Terminated
Solid Tumour|Advanced Solid Malignancies|Child-Pugh A to B7 Advanced Hepatocellular Carcinoma|EGFR and/or ROS Mutant NSCLC|Lung Metastasis Carcinoma|Gastric Cancer
AstraZeneca
November 2010 Phase 1
NCT01112397 Terminated
Solid Malignancies
AstraZeneca
April 2010 Phase 1

기술 지원

취급 설명서

Tel: +1-832-582-8158 Ext:3

다른 문의사항이 있으시면 메시지를 남겨주세요.

이름을 입력해주세요.
이메일을 입력해주세요. 유효한 이메일 주소를 입력해주세요.
저희에게 무엇이든 작성해주세요.